A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Recruiting
Phase 3Interventional Study
Depressive Disorder, Major
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
1,000 (estimated)
Sponsor
Eli Lilly and Company · Industry
Who this trial is looking for
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a treatment period that will last a minimum of 12 months, and the follow up period that will last appr…
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a treatment period that will last a minimum of 12 months, and the follow up period that will last approximately 2 months. The duration of study participation may vary and may be shortened if depression symptoms worsen or if withdrawal from the study occurs for any reason.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Meet the diagnostic criteria for major depressive disorder
* Are on a stable standard of care medication for major depressive disorder
* Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and ab…
Inclusion Criteria:
* Meet the diagnostic criteria for major depressive disorder
* Are on a stable standard of care medication for major depressive disorder
* Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and able to follow study procedures as required, such as
* self-inject study intervention
* store and use the provided blinded study intervention, as directed
* maintain electronic and paper study diaries, as applicable, and
* complete the required questionnaires
Exclusion Criteria:
* Have a lifetime history or current diagnosis of the following:
* schizophrenia or other psychotic disorder
* bipolar disorder
* borderline personality disorder, or
* any eating disorder.
* Have type 1 diabetes mellitus, or a history of
* ketoacidosis, or
* hyperosmolar state or coma.
* Evidence of moderate or severe substance or alcohol use disorder within 180 days of screening
* Are actively suicidal or deemed a significant risk for suicide
* Have participated in a clinical study and received active treatment, or unknown if they received active treatment, within 90 days or 5 half-lives (whichever is longer) before screening
Contacts
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.